You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海正藥業(600267.SH):擬與箇中諮詢共同投資設立浙江贊生藥業
格隆匯 08-05 19:01

格隆匯 8 月 5日丨海正藥業(600267.SH)公佈,公司第八屆董事會第十五次會議決議,審議通過關於投資設立中藥項目合資公司的議案

同意公司與杭州箇中企業管理諮詢中心(有限合夥)(“箇中諮詢”)共同投資設立浙江贊生藥業有限公司(暫定名,以工商部門核准登記為準;“合資公司”)。

根據北京北方亞事資產評估事務所(特殊普通合夥)出具的《浙江海正藥業股份有限公司擬以資產出資新設公司涉及的中成藥生產線固定資產及無形資產價值資產評估報告》(北方亞事評報字[2020]01-399)20191231日為評估基準日,採用成本法進行評估,公司以資產出資涉及的中成藥生產線相關的固定資產和“通絡生骨膠囊”、“小柴胡膠囊”、“香通片”、“心腦欣片”、“大山楂咀嚼片”、“香歸逍遙顆粒”6個藥品批准文號及相關藥品生產技術無形資產評估價值為10910萬元。參考評估價值公司以上述資產作價人民幣1.2億元出資,其中0.4億元計入註冊資本,佔合資公司註冊資本的40%,超過部分的0.8億元計入資本公積。箇中諮詢以現金1.8億元出資,其中0.6億元計入註冊資本,佔合資公司註冊資本的60%,超過部分的1.2億元計入資本公積。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account